SAba Sile
Corporate Officer/Principal chez SPRUCE BIOSCIENCES, INC.
Profil
SAba Sile is currently the Vice President-Clinical Development at Spruce Biosciences, Inc. Prior to this, Sile worked as a Medical Director at BioMarin Pharmaceutical, Inc. and as an Executive Medical Director-Clinical Development at Horizon Therapeutics Plc.
Sile holds a doctorate degree from the University of Pittsburgh School of Medicine.
Postes actifs de SAba Sile
| Sociétés | Poste | Début |
|---|---|---|
| SPRUCE BIOSCIENCES, INC. | Corporate Officer/Principal | 10/11/2022 |
Anciens postes connus de SAba Sile
| Sociétés | Poste | Fin |
|---|---|---|
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Corporate Officer/Principal | - |
| BIOMARIN PHARMACEUTICAL INC. | Corporate Officer/Principal | - |
Formation de SAba Sile
| University of Pittsburgh School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| SPRUCE BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Horizon Therapeutics Plc
 Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
